Table 3.

Combined targeting of multiple targets or epitopes.

Target molecule	IR700 carrier	TSPC	Cancer	Combination treatment	Tumor model	Ref.
EGFR, HER2	Antibody	Pan-IR700, Tra-IR700	Cholangiocarci-noma		In vitro and in vivo; s.c.	135
EGFR, HER2	Antibody	Pan-IR700, Tra-IR700	Bladder cancer		In vitro and in vivo; s.c.	86
EGFR, HER2	Antibody	Cet-IR700, Tra-IR700	Esophageal adenocarcinoma	TKI	In vitro	51
EGFR, HER2	Antibody	Cet-IR700, Tra-IR700	Cutaneous squamous cell carcinoma		In vitro and in vivo; s.c.	20
EGFR, CD25	Antibody	Pan-IR700, Bas-IR700	Cutaneous squamous cell carcinoma		In vitro and in vivo; s.c.	27
EGFR, EpCAM and CSPG4	ScFv	ScFv-425 (EGFR), EpCAM(scFv), CSPG4(scFv), -SNAP-IR700	Triple-negative breast cancer cell lines		In vitro	49
CD44, CD25	Antibody	Anti-CD44-IR700, anti-CD25-IR700	Colon cancer, lung carcinoma, oral carcinoma		In vitro and in vivo; s.c.	83

TKI: tyrosine kinase inhibitor; s.c, subcutaneous